User Profile
Corporate
Careers
FAQ
Blog
Pricing
Social
General Modals
Advanced Modals
Search
Wizards
2025 LCRF Research Grant on Overcoming Resistance in Lung Cancer
Lung cancer is responsible for more deaths worldwide than any other cancer accounting for an estimated 125,070 deaths annually in the United States alone1 . The last 10-15 years have seen accelerated clinical trials and FDA approvals of numerous lung cancer therapies including several targeted and immunotherapies. Despite these advances drug resistance limits the therapeutic potential of these treatments and there is a need to understand mechanisms of drug resistance and develop approaches to overcome and prevent resistance. In 2025, in partnership with leading patient advocacy organizations, this grant mechanism will focus on furthering the understanding of the development, prevention, and therapy of resistance by supporting projects that seek to identify, characterize, treat or prevent resistance to lung cancer therapies. Work supported through this mechanism will address important mechanistic questions and developmental therapeutics across histological subtypes of lung cancer (including lung adenocarcinoma, squamous cell carcinoma and small cell lung cancer) and across the care continuum including newly designed targeted therapies and immunotherapies. These studies will enhance the momentum of improving lung cancer outcomes and have the potential to increase survivorship.
We encourage applications on a wide variety of topics related to understanding and/or overcoming resistance including but not limited to:
• Mechanisms of resistance to targeted therapies for oncogene-driven lung cancers. Proposals are encouraged in the areas of histological transformation, oligometastatic disease, oligo-remnant disease, uncommon mutations and non-genomic mechanisms of resistance.
• Biology and mechanisms of drug resistance to lung cancer therapies including chemotherapy, immunotherapy, radiotherapy, and antibody drug conjugates.
• Novel treatment approaches and new therapies to overcome and/or prevent resistance to lung cancer therapies.
• Novel diagnostic approaches (i.e. biomarkers) to monitor treatment response and relapse.
• Overcoming resistance in difficult to treat sites of metastases such as leptomeningeal and brain metastases.
Budget Requirements
The maximum award amount is $150,000 for a period of two years (disbursed at $75,000 per year). Additional budget requirements and considerations include the following:
• Funding from this award may not be used to support institutional indirect / facilities and administrative costs.
• The LCRF grant must be the primary source of support for the project. Additional secondary funding (e.g. for core services support) is permitted.
• There is no limit on the amount of salary support that may be requested. However, appropriate justification for all budget items is required. Any salary requests in excess of 20% of the total budget must be explicitly justified. Queries related to justification should be sent to LCRF at least a week before submission deadline.
• Any equipment costs must be limited and directly applicable to the research project (i.e. large, general equipment costs are not permitted).
• Direct patient care costs reimbursable by other sources may not be included.
• Travel and publication costs are permitted.
Specialties
Eligibility Requirements
Investigators must be affiliated with a non-profit academic or research institution and must be post-doctoral researchers, clinical fellows, or early-career and mid-career investigators with less than ten years’ experience since their initial faculty appointment.
Applicants from US-based and international institutions are eligible to apply and may hold any residency/citizenship status. Applicants are prohibited from applying if they have received funding from the LCRF within the last 4 years. Applicants are prohibited from applying in more than one of LCRF’s funding tracks in the same cycle. Senior investigators with more than ten years’ experience since faculty appointment are generally not eligible for funding and are encouraged to mentor a junior team member through the application process. However, exceptions will be made for investigators with more than ten years’ experience in other disease areas or topics. Ineligible investigators with these or other special circumstances may request review by contacting the LCRF grants office (see Inquiries section below) before submitting an application and at least a week before submission deadline. Ineligible applications and new requests under special circumstances will not be considered after submission deadline.
Sponsor Details
Sponsor Institute/Organizations: Lung Cancer Research Foundation
Sponsor Type:
Address: 501 7th Avenue, Suite 401 New York, NY 10018 United States
Legal & Affiliation Disclaimer
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Grant
Letter Of Intent Deadline:
Mar 03, 2025
Final Deadline:
Jun 02, 2025
Funding Amount:
$150,000
Host Details
Affiliation: Lung Cancer Research Foundation
Address: 501 7th Avenue, Suite 401 New York, NY 10018 United States
Website URL: https://www.lungcancerresearchfoundation.org/wp-content/uploads/2025-LCRF-OvercomingResistance-RFP.pdf
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.
Invite Gmail Contacts